Arovella Therapeutics Limited




Biotechnology & Medical Research

Market Closed - Australian Stock Exchange 12:11:00 2023-12-11 am EST Intraday chart for Arovella Therapeutics Limited 5-day change 1st Jan Change
0.091 AUD +3.41% -3.19% +295.65%
This article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Arovella Therapeutics Ltd. Announces Change of Company Address CI
Arovella Therapeutics Appoints CFO MT
Arovella Therapeutics Limited Announces Changes to its Board CI
Arovella Therapeutics Limited Announces Executive Changes CI
Arovella Therapeutics Secures AU$2 Million Tax Rebate for Fiscal Year 2023 MT
Australian Shares Flat With Positive Bias Amid Hopes of US Fed Keeping Rates Steady MT
Arovella Therapeutics Secures License for Tumor Targeting Antibody; Shares Fall 6% MT
Arovella Therapeutics Limited Announces Retirement of David Simmonds as Non-Executive Director CI
Arovella Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Arovella Therapeutics Raises AU$2.2 Million From Oversubscribed Share Purchase Plan MT
Arovella Therapeutics Extends Closing Date of Share Purchase Plan MT
Arovella Therapeutics, UNC Further Discussions on Enhanced iNKT Cells Performance MT
Arovella Therapeutics Ends AU$4.1 Million Placement; Launches AU$1 Million Purchase Plan MT
Arovella Therapeutics Completes Closure of Perth R&D Facility MT
Arovella Therapeutics Appoints Nonexecutive Chair MT
Arovella Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2022 CI
Arovella, Imugene's Collaboration on Tumor Cells Therapy Progresses to Next Phase MT
Arovella Therapeutics Limited and Imugene Announces Collaboration Advances to Next Phase of Testing CI
Arovella Therapeutics Appoints COO MT
Arovella Therapeutics Ltd Appoints Dr. Nicole Van Der Weerden as Chief Operating Officer, January 4, 2023 CI
Arovella Therapeutics Secures Exclusive Option to License Cytokine Technology for Cancer Therapy Platform MT
Arovella Therapeutics Ltd Options Cytokine Technology to Enhance iNKT platform CI
Arovella Therapeutics Receives R&D Tax Rebate MT
Arovella Therapeutics Limited Announces Europe Patent to Be Granted for Inkt Cell Therapy Platform CI
Arovella Therapeutics to Close Perth R&D Facility in Q1 2023 MT
Chart Arovella Therapeutics Limited
More charts
Arovella Therapeutics Limited is an Australia-based biotechnology company. The Company is focused on developing therapies to treat human disease. The Company focuses two focus areas are oncology and conditions that impact the central nervous system. The Company's technology includes iNKT Cell Therapy, DKK1-CAR-iNKT, AR19-iNKT + CF33-CD19, Anagrelide and ZolpiMist. The Company's invariant natural killer T (iNKT) cell therapy pipeline through the license to the DKK1 monoclonal antibody (mAb). It develops the DKK1 mAb as a chimeric antigen receptor to use in combination with its iNKT cell therapy platform. The Company is developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumors. Anagrelide is for the treatment of metastatic disease granted in the United States, Europe, Japan and Australia. ZolpiMist is an oral spray of zolpidem tartrate to treat short- term insomnia.
More about the company

Annual profits - Rate of surprise

Secure and Increase the Performance of your Investments with our Team of Experts at your Side
Securing my Investments